Search Results - "Rizzieri, A"

Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm by Pemmaraju, Naveen, Lane, Andrew A, Sweet, Kendra L, Stein, Anthony S, Vasu, Sumithira, Blum, William, Rizzieri, David A, Wang, Eunice S, Duvic, Madeleine, Sloan, J. Mark, Spence, Sharon, Shemesh, Shay, Brooks, Christopher L, Balser, John, Bergstein, Ivan, Lancet, Jeffrey E, Kantarjian, Hagop M, Konopleva, Marina

“…Patients with blastic plasmacytoid dendritic-cell neoplasm, an aggressive hematologic cancer, were treated with the cytotoxin tagraxofusp in a dose-escalation…”
Get full text

The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia by Stein, Eytan M., Garcia-Manero, Guillermo, Rizzieri, David A., Tibes, Raoul, Berdeja, Jesus G., Savona, Michael R., Jongen-Lavrenic, Mojca, Altman, Jessica K., Thomson, Blythe, Blakemore, Stephen J., Daigle, Scott R., Waters, Nigel J., Suttle, A. Benjamin, Clawson, Alicia, Pollock, Roy, Krivtsov, Andrei, Armstrong, Scott A., DiMartino, Jorge, Hedrick, Eric, Löwenberg, Bob, Tallman, Martin S.

“…Pinometostat (EPZ-5676) is a first-in-class small-molecule inhibitor of the histone methyltransferase disrupter of telomeric silencing 1-like (DOT1L). In this…”
Get full text

Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial by ARMAND, Philippe, NAGLER, Arnon, FAY, Joseph W, RIZZIERI, David A, HOSING, Chitra M, BALL, Edward D, UBERTI, Joseph P, LAZARUS, Hillard M, MAPARA, Markus Y, GREGORY, Stephanie A, TIMMERMAN, John M, ANDORSKY, David, WELLER, Edie A, OR, Reuven, WALLER, Edmund K, ROTEM-YEHUDAR, Rinat, GORDON, Leo I, DEVINE, Steven M, AVIGAN, David E, CHEN, Yi-Bin, KAMINSKI, Mark S, KENT HOLLAND, H, WINTER, Jane N, MASON, James R

“…The Programmed Death-1 (PD-1) immune checkpoint pathway may be usurped by tumors, including diffuse large B-cell lymphoma (DLBCL), to evade immune…”
Get full text

Hematopoietic Stem-Cell Transplantation for Acute Leukemia in Relapse or Primary Induction Failure by DUVAL, Michel, KLEIN, John P, KEATING, Armand, LAZARUS, Hillard M, LITZOW, Mark R, MARKS, David I, MAZIARZ, Richard T, RIZZIERI, David A, SCHILLER, Gary, SCHULTZ, Kirk R, TALLMAN, Martin S, WEISDORF, Daniel, WENSHENG HE, CAHN, Jean-Yves, CAIRO, Mitchell, CAMITTA, Bruce M, KAMBLE, Rammurti, COPELAN, Edward, DE LIMA, Marcos, GUPTA, Vikas

“…Patients with acute leukemia refractory to induction or reinduction chemotherapy have poor prognoses if they do not undergo hematopoietic stem-cell…”
Get full text

Targeting of the MNK–eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function by Lim, Sharon, Saw, Tzuen Yih, Zhang, Min, Janes, Matthew R, Nacro, Kassoum, Hill, Jeffrey, Lim, An Qi, Chang, Chia-Tien, Fruman, David A, Rizzieri, David A, Tan, Soo Yong, Fan, Hung, Chuah, Charles T H, Ong, S Tiong

“…Chronic myeloid leukemia responds well to therapy targeting the oncogenic fusion protein BCR-ABL1 in chronic phase, but is resistant to treatment after it…”
Get full text

A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies by Rizzieri, David A, Feldman, Eric, Dipersio, John F, Gabrail, Nashat, Stock, Wendy, Strair, Roger, Rivera, Victor M, Albitar, Maher, Bedrosian, Camille L, Giles, Francis J

“…Purpose: Deforolimus (AP23573), a novel non-prodrug rapamycin analogue, inhibits the mammalian target of rapamycin, a downstream effector of the…”
Get full text

Patterns of microRNA expression characterize stages of human B-cell differentiation by Zhang, Jenny, Jima, Dereje D., Jacobs, Cassandra, Fischer, Randy, Gottwein, Eva, Huang, Grace, Lugar, Patricia L., Lagoo, Anand S., Rizzieri, David A., Friedman, Daphne R., Weinberg, J. Brice, Lipsky, Peter E., Dave, Sandeep S.

“…Mature B-cell differentiation provides an important mechanism for the acquisition of adaptive immunity. Malignancies derived from mature B cells constitute the…”
Get full text

Hematopoietic Engraftment and Survival in Adult Recipients of Umbilical-Cord Blood from Unrelated Donors by Laughlin, Mary J, Barker, Juliet, Bambach, Barbara, Koc, Omer N, Rizzieri, David A, Wagner, John E, Gerson, Stanton L, Lazarus, Hillard M, Cairo, Mitchell, Stevens, Cladd E, Rubinstein, Pablo, Kurtzberg, Joanne

“…Umbilical-cord blood from unrelated donors can restore hematopoiesis in adults who receive myeloablative therapy. Transplantation of allogeneic hematopoietic…”
Get full text

Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis by Khoury, H J, Kukreja, M, Goldman, J M, Wang, T, Halter, J, Arora, M, Gupta, V, Rizzieri, D A, George, B, Keating, A, Gale, R P, Marks, D I, McCarthy, P L, Woolfrey, A, Szer, J, Giralt, S A, Maziarz, R T, Cortes, J, Horowitz, M M, Lee, S J

“…Allogeneic hematopoietic SCT is an effective treatment in accelerated (AP) or blast phase (BP) CML. Imatinib (IM) has transient but significant activity in…”
Get full text

Pre-transplant hepatic steatosis (fatty liver) is associated with chronic graft-vs-host disease but not mortality by Maung, Ko, Ramalingam, Sendhilnathan, Chaudhry, Mohammad, Ren, Yi, Jung, Sin-Ho, Romero, Kristi, Corbet, Kelly, Chao, Nelson J, Choi, Taewoong, Diehl, Anna Mae, Diehl, Louis, Gasparetto, Cristina, Horwitz, Mitchell, Long, Gwynn Douglas, Lopez, Richard D, Rizzieri, David A, Sarantopoulos, Stefanie, Sullivan, Keith M, Bashir, Mustafa R, Sung, Anthony D

“…Allogeneic-HCT (allo-HCT), while potentially curative, can result in significant complications including graft versus host disease (GVHD). Prior studies…”
Get full text

The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia, stem cells by JORDAN, C. T, UPCHURCH, D, LUGER, S. M, PHILLIPS, G. L, SZILVASSY, S. J, GUZMAN, M. L, HOWARD, D. S, PETTIGREW, A. L, MEYERROSE, T, ROSSI, R, GRIMES, B, RIZZIERI, D. A

“…Recent studies suggest that the population of malignant cells found in human acute myelogenous leukemia (AML) arises from a rare population of leukemic stem…”
Get full text

Severe Pulmonary Toxicity After Myeloablative Conditioning Using Total Body Irradiation: An Assessment of Risk Factors by Kelsey, Chris R., M.D, Horwitz, Mitchell E., M.D, Chino, Junzo P., M.D, Craciunescu, Oana, Ph.D, Steffey, Beverly, M.S, Folz, Rodney J., M.D. Ph.D, Chao, Nelson J., M.D, Rizzieri, David A., M.D, Marks, Lawrence B., M.D

“…Purpose To assess factors associated with severe pulmonary toxicity after myeloablative conditioning using total body irradiation (TBI) followed by allogeneic…”
Get full text

Partially Matched, Nonmyeloablative Allogeneic Transplantation: Clinical Outcomes and Immune Reconstitution by RIZZIERI, David A, LIANG PIU KOH, NIEDZWIECKI, Donna, DOWELL, Jeannette M, WATERS-PICK, Barbara, CONGXIAO LIU, MARSHALL, Dawn, VREDENBURGH, James J, GOCKERMAN, Jon, DECASTRO, Carlos, MOORE, Joseph, CHAO, Nelson J, LONG, Gwynn D, GASPARETTO, Cristina, SULLIVAN, Keith M, HORWITZ, Mitchell, CHUTE, John, SMITH, Clayton, GONG, Jerald Z, LAGOO, Anand

“…Allogeneic transplantation is typically limited to younger patients having a matched donor. To allow a donor to be found for nearly all patients, we have used…”
Get full text

Genetic heterogeneity of diffuse large B-cell lymphoma by Zhang, Jenny, Grubor, Vladimir, Love, Cassandra L., Banerjee, Anjishnu, Richards, Kristy L., Mieczkowski, Piotr A., Dunphy, Cherie, Choi, William, Au, Wing Yan, Srivastava, Gopesh, Lugar, Patricia L, Rizzieri, David A., Lagoo, Anand S., Bernal-Mizrachi, Leon, Mann, Karen P., Flowers, Christopher, Naresh, Kikkeri, Evens, Andrew, Gordon, Leo I., Czader, Magdalena, Gill, Javed I., Hsi, Eric D., Liu, Qingquan, Fan, Alice, Walsh, Katherine, Jima, Dereje, Smith, Lisa L., Johnson, Amy J., Byrd, John C., Luftig, Micah A., Ni, Ting, Zhu, Jun, Chadburn, Amy, Levy, Shawn, Dunson, David, Dave, Sandeep S.

“…Diffuse large B-cell lymphoma (DLBCL) is the most common form of lymphoma in adults. The disease exhibits a striking heterogeneity in gene expression profiles…”
Get full text

Alemtuzumab for the prevention and treatment of graft-versus-host disease by Kanda, Junya, Lopez, Richard D., Rizzieri, David A.

“…Alemtuzumab is a humanized monoclonal antibody against the CD52 antigen, which is expressed on the surface of various hematopoietic cells such as B and T…”
Get full text

Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: risk factors and response to treatment by Kanda, J, Kaynar, L, Kanda, Y, Prasad, V K, Parikh, S H, Lan, L, Shen, T, Rizzieri, D A, Long, G D, Sullivan, K M, Gasparetto, C, Chute, J P, Morris, A, Winkel, S, McPherson, J, Kurtzberg, J, Chao, N J, Horwitz, M E

“…High fevers and/or rashes prior to neutrophil engraftment are frequently observed after umbilical cord blood (UCB) transplantation, and the condition is…”
Get full text

Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration by Horwitz, M E, Chute, J P, Gasparetto, C, Long, G D, McDonald, C, Morris, A, Rizzieri, D A, Sullivan, K M, Chao, N J

“…Plerixafor, given on day 4 of G-CSF treatment is more effective than G-CSF alone in mobilizing hematopoietic progenitor cells. We tested a strategy of…”
Get full text

Morphologic leukemia-free state in acute myeloid leukemia is sufficient for successful allogeneic hematopoietic stem cell transplant by Pabon, Cindy M., Li, Zhiguo, Hennig, Therese, de Castro, Carlos, Neff, Jadee L., Horwitz, Mitchell E., LeBlanc, Thomas W., Long, Gwynn D., Lopez, Richard D., Sung, Anthony D., Chao, Nelson, Gasparetto, Cristina, Sarantopoulos, Stefanie, Adams, Donna B., Erba, Harry, Rizzieri, David A.

Get full text

High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma by Sivaraj, D, Bacon, W, Long, G D, Rizzieri, D A, Horwitz, M E, Sullivan, K M, Kang, Y, Li, Z, Chao, N J, Gasparetto, C

“…Single-agent high-dose melphalan (HDM, 200 mg/m 2 ) has been the most commonly used conditioning regimen prior to autologous stem cell transplant, since its…”
Get full text

Nuclear factor-κB is constitutively activated in primitive human acute myelogenous leukemia cells by Guzman, Monica L., Neering, Sarah J., Upchurch, Donna, Grimes, Barry, Howard, Dianna S., Rizzieri, David A., Luger, Selina M., Jordan, Craig T.

“…Human acute myelogenous leukemia (AML) is thought to arise from a rare population of malignant stem cells. Cells of this nature, herein referred to as leukemic…”
Get full text